As Gout Market Opens Up, Experts Await Therapies To Better Lower Uric Acid
This article was originally published in Pharmaceutical Approvals Monthly
PHILADEPHIA – Though Takeda's gout therapy Uloric (febuxostat) has broken a 40-year dry spell in the market, physicians and researchers are hoping more drugs will be approved that can reduce serum uric acid well below the standard 6 mg/dL benchmark. Safety, though, could be a hang-up.
You may also be interested in...
Pricing for Duzallo, a fixed-dose combination of Zurampic (lesinurad) with generic allopurinol, will likely be on par with Zurampic's solo price tag of $371 per month to smooth the way with payers.
The $1.26 billion buyout comes as the pharma is looking to bolt-on acquisitions to help offset recent late-stage pipeline disappointments and sees Ardea’s lesinurad as a potential improvement in gout therapy, an estimated $2 billion global market.
In purchasing privately held URL for $800 million, Takeda acquires gout drug Colcrys, which it will market alongside Uloric.